From University Invention to Real Product: Who Must Prove What before the First Customer Buys

Start with the customer’s constraint

A research result can be technically impressive while remaining commercially incomplete. The relevant gap is often not another scientific breakthrough but an unanswered operational question: who will use it, under what conditions and with what measurable benefit? WIPO’s technology-transfer guidance recognises that university inventions may still be laboratory prototypes needing further development. The analysis here builds on that distinction. A publication, patent, demonstration and purchased product are different forms of progress; none should be used as a substitute for the evidence required at the next stage.

A useful starting document describes the customer’s current workaround, the cost of that workaround and the circumstances in which it fails. That document should also name the person who would approve a purchase. An enthusiastic technical contact may not control a budget or a procurement process. This is an analytical recommendation, not a reported feature of any Qatar University agreement. Its purpose is to expose a basic risk early: a team can solve an interesting problem while remaining disconnected from the organisation that must pay to use the solution.

Licensing and a spinout answer different needs

Licensing allows an organisation to use intellectual property within agreed terms. A university spinout is a company created to develop research-based assets; it may itself need a licence from the university. The two concepts are therefore not mutually exclusive. The strategic choice is whether an existing company can bring the necessary capabilities, or whether a dedicated organisation must be built around the opportunity. WIPO identifies several transfer routes, including licensing, research collaboration and new companies. The appropriate route depends on the technology, market and available team.

An established business may already have manufacturing, customer relationships and support systems. A new company may offer sharper focus when the invention does not fit an incumbent’s priorities. But a spinout also creates work unrelated to the science: recruitment, financing, sales and organisational control. Choosing it because a new-company announcement sounds more ambitious confuses the vehicle with the destination. Conversely, granting rights to an existing firm is not automatically a faster route if that firm lacks a committed team, development budget or credible reason to prioritise the project.

Separate the rights from the capabilities

A licence resolves permission within its contractual scope; it does not manufacture the product or create a sales channel. Teams need to identify what else must move: know-how, software, samples, designs, training or continuing access to specialist expertise. The terms also need to address who can develop improvements and how those improvements relate to the original rights. These are questions for the parties and their advisers, not universal contractual answers. Public announcements rarely contain enough detail to establish how a particular transaction has allocated all of these responsibilities.

Exclusive rights can justify investment when development is expensive and competitors could otherwise benefit from the same asset. They can also leave technology inactive if the chosen partner does little. A non-exclusive model can broaden use but may change how much any one developer is willing to spend. The useful negotiation asks which incentives make progress likely and what happens if progress stalls. Scope and milestones matter alongside headline exclusivity. A territory-wide right with no execution capacity may be less valuable in practice than a narrower arrangement supported by a capable delivery team.

Define proof before running the pilot

A demonstration asks whether something can work. A customer pilot should ask whether it works well enough in the intended environment to justify the next decision. That difference changes the design of the exercise. Before testing, define the baseline, the outcome being measured, the conditions that count as representative and who will interpret the results. If the trial only reproduces ideal laboratory conditions, it may add little information about deployment. If it changes many variables at once, it may be difficult to understand why performance improved or deteriorated.

Consider a clearly hypothetical example: a materials startup tests a new coating on industrial equipment. A useful pilot would specify the comparison surface, operating conditions, inspection method and acceptable performance before installation. It would also identify who pays for downtime and who can stop the test if problems appear. No performance threshold is proposed here because the correct threshold depends on the application. The point is procedural: an agreed test turns disagreement into evidence, while an undefined trial can produce months of activity without a decision anyone is obliged to make.

Give the pilot customer a bounded role

A pilot customer is not automatically an investor, distributor, regulator or guaranteed buyer. It may simply provide a realistic place to test and staff who understand the operating problem. That contribution has value and costs. Access to equipment, employee time and operational data should be agreed rather than treated as free resources. The technology team should also explain what it needs from the customer each week. A partnership becomes fragile when the company expects intensive collaboration while the host believes it has only agreed to lend a location.

The route after the pilot should be discussed before it ends. If the results meet the agreed criteria, will there be a procurement review, a larger test or a negotiated commercial proposal? A pilot does not have to guarantee a purchase to be worthwhile, but the decision process should be visible. Otherwise, teams can become trapped in serial trials that generate praise without orders. In a small market, this can consume scarce technical time and create the appearance of traction while postponing the harder test of whether someone will pay.

Build the product around support and repeatability

The first working unit can depend on the inventor’s constant attention. A product must eventually work without that person standing beside every customer. Documentation, installation procedures, training and support are therefore part of development, not decorative additions after the science is complete. The same applies to sourcing and consistency: a prototype made with exceptional effort may not be affordable or reproducible at the required volume. These are commercial questions that can be investigated early, even before a company commits to a full manufacturing or distribution model.

In regulated or safety-sensitive applications, the evidence and authorisations relevant to the intended use must be addressed specifically. A research paper, patent or university endorsement does not replace them. This does not mean every project faces the same pathway or timetable; requirements depend on the product and jurisdiction. A responsible team maps the relevant decisions and obtains qualified advice for its actual case. For readers assessing announcements, the key discipline is to distinguish promising evidence from an authorisation, and an authorisation from demonstrated performance in routine customer use.

Measure a pipeline by decisions, not signatures alone

Qatar University’s announcement on 8 November establishes four licensing agreements with two local companies, covering marine and health technologies. It does not disclose all future development outcomes. The wider lesson for a regional innovation system is to track what happens after the rights are granted: which uncertainty was reduced, which capability was built and which customer decision became possible. Patent totals and agreement counts can indicate activity, but they cannot alone establish adoption, commercial sustainability or public benefit. Those outcomes require their own measures and honest follow-up.

A strong commercialisation process makes responsibility legible. The university identifies and manages its research assets; the developer builds a deliverable proposition; the pilot host supplies an agreed test setting; and the eventual buyer evaluates a purchase against its needs. Actual contracts may distribute tasks differently, but the allocation must be understood. The strategic objective is not to eliminate uncertainty before anyone acts. It is to spend money and attention on the next uncertainty that matters, with a clear decision waiting on the other side of the evidence.

Gabriel Nicolaev – CyGuru